Evaluation of not-activated and activated PRP in hair loss treatment: Role of growth factor and cytokine concentrations obtained by different collection systems

International Journal of Molecular Sciences

Volumn 18, Issue 2, 2017, Pages

  Gentile, Pietro ^a,b   Cole, John P ^c   Cole, Megan A ^c   Garcovich, Simone ^d   Bielli, Alessandra ^a   Scioli, Maria Giovanna ^a   Orlandi, Augusto ^a   Insalaco, Chiara ^a,c   Cervelli, Valerio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b CATHOLIC UNIVERSITY OUR LADY OF GOOD COUNSEL   (Albania)

^c Cole Hair Transplant Group ^*  (United States)

^d CATHOLIC UNIVERSITY   (Italy)

Author keywords

Activated PRP; Androgenic alopecia; Autologous PRP; Growth factors; Hair loss

Indexed keywords

CORTICOSTEROID; MINOXIDIL; PLATELET DERIVED GROWTH FACTOR BB; PRION PROTEIN; RETINOID; SOMATOMEDIN C RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN; CYTOKINE; SIGNAL PEPTIDE;

ADULT; ARTICLE; CELL THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HAIR LOSS; HAIR TRANSPLANTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MALE TYPE ALOPECIA; PROTEIN EXPRESSION; THROMBOCYTE RICH PLASMA; ALOPECIA; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HAIR; HAIR FOLLICLE; METABOLISM; MIDDLE AGED; PATHOLOGY; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ALOPECIA; CYTOKINES; HAIR; HAIR FOLLICLE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; PLATELET-RICH PLASMA; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85012977956     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18020408     Document Type: Article

References (48)

1. Ellis, J.A.; Sinclair, R.; Harrap, S.B. Androgenetic alopecia: Pathogenesis and potential for therapy. Expert Rev. Mol. Med. 2002, 4, 1–11.
2. Rogers, N.E.; Avram, M.R. Medical treatments for male and female pattern hair loss. J. Am. Acad. Dermatol. 2008, 59, 547–566.
3. Gupta, M.; Mysore, V. Classifications of patterned hair loss: A review. J. Cutan. Aesthet. Surg. 2016, 9, 3–12.
4. Levy, L.L.; Emer, J.J. Female pattern alopecia: Current perspectives. Int. J. Women Health 2013, 5, 541–556.
5. Rousso, D.E.; Kim, S.W. A review of medical and surgical treatment options for androgenetic alopecia. JAMA Facial Plast. Surg. 2014, 16, 444–450.
6. Schweiger, E.S.; Boychenko, O.; Bernstein, R.M. Update on the pathogenesis, genetics and medical treatment of patterned hair loss. J. Drugs Dermatol. 2010, 9, 1412–1419.
7. Price, V.H.; Roberts, J.L.; Hordinsky, M.; Olsen, E.A.; Savin, R.; Bergfeld, W.; Fiedler, V.; Lucky, A.; Whiting, D.A.; Pappas, F.; et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J. Am. Acad. Dermatol. 2000, 43, 768–776.
8. Imperato-McGinley, J.; Guerrero, L.; Gautier, T.; Peterson, R.E. Steroid 5α-reductase deficiency in man: An inherited form of male pseudohermaphroditism. Science 1974, 186, 1213–1215.
9. Drake, L.; Hordinsky, M.; Fiedler, V.; Swinehart, J.; Unger, W.P.; Cotterill, P.C.; Thiboutot, D.M.; Lowe, N.; Jacobson, C.; Whiting, D.; et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J. Am. Acad. Dermatol. 1999, 41, 550–554.
10. Van Neste, D.; Fuh, V.; Sanchez-Pedreno, P.; Lopez-Bran, E.; Wolff, H.; Whiting, D.; Roberts, J.; Kopera, D.; Stene, J.J.; Calvieri, S.; et al. Finasteride increases anagen hair in men with androgenetic alopecia. Br. J. Dermatol. 2000, 143, 804–810.
11. Kaufman, K.D.; Olsen, E.A.; Whiting, D.; Savin, R.; DeVillez, R.; Bergfeld, W.; Price, V.H.; van Neste, D.; Roberts, J.L.; Hordinsky, M.; et al. Finasteride in the treatment of men with androgenetic alopecia. J. Am. Acad. Dermatol. 1998, 39, 578–589.
12. Savin, R.C. Use of topical minoxidil in the treatment of male pattern baldness. J. Am. Acad. Dermatol. 1987, 16, 696–704.
13. Whiting, D.A.; Jacobson, C. Treatment of female androgenetic alopecia with minoxidil 2%. Int. J. Dermatol. 1992, 31, 800–804.
14. Olsen, E.A.; Dunlap, F.E.; Funicella, T.; Koperski, J.A.; Swinehart, J.M.; Tschen, E.H.; Trancik, R.J. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J. Am. Acad. Dermatol. 2002, 47, 377–385.
15. Tsuboi, R.; Arano, O.; Nishikawa, T.; Yamada, H.; Katsuoka, K. Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men. J. Dermatol. 2009, 36, 437–446.
16. Olsen, E.A.; Weiner, M.S. Topical minoxidil in male pattern baldness: Effects of discontinuation of treatment. J. Am. Acad. Dermatol. 1987, 17, 97–101.
17. Nandi, S.; Brown, A.C. Platelet-mimetic strategies for modulating the wound environment and inflammatory responses. Exp. Biol. Med. 2016, 241, 1138–1148.
18. Nurden, A.T. Platelets, inflammation and tissue regeneration. Thromb. Haemost. 2011, 105, S13–S33.
19. Afifi, L.; Maranda, E.L.; Zarei, M.; Delcanto, G.M.; Falto-Aizpurua, L.; Kluijfhout, W.P.; Jimenez, J.J. Low-level laser therapy as a treatment for androgenetic alopecia. Lasers Surg Med. 2017, 49, 27–39.
20. Jones, M.E.; Hardy, C.; Ridgway, J. Keloid management: A retrospective case review on a new approach using surgical excision, platelet-rich plasma, and in-office superficial photon X-ray radiation therapy. Adv. Skin Wound Care 2016, 29, 303–307.
21. Naik, A.R.; Ramesh, A.V.; Dwarkanath, C.D.; Naik, M.S.; Chinnappa, A.B. Use of autologous platelet rich plasma to treat gingival recession in esthetic periodontal surgery. J. Indian Soc. Periodontol. 2013, 17, 345-353.
22. Klosová, H.; Štětinský, J.; Bryjová, I.; Hledík, S.; Klein, L. Objective evaluation of the effect of autologous platelet concentrate on post-operative scarring in deep burns. Burns 2013, 39, 1263–1276.
23. Motolese, A.; Vignati, F.; Antelmi, A.; Saturni, V. Effectiveness of platelet-rich plasma in healing necrobiosis lipoidica diabeticorum ulcers. Clin. Exp. Dermatol. 2015, 40, 39–41.
24. Gawdat, H.I.; Hegazy, R.A.; Fawzy, M.M.; Fathy, M. Autologous platelet rich plasma: Topical versus intradermal after fractional ablative carbon dioxide laser treatment of atrophic acne scars. Dermatol. Surg. 2014, 40, 152–161.
25. Zucker, M.B.; Nachmias, V.T. Platelet activation. Arteriosclerosis 1985, 5, 2–18.
26. Uebel, C.O.; da Silva, J.B.; Cantarelli, D.; Martins, P. The role of platelet plasma growth factors in male pattern baldness surgery. Plast. Reconstr. Surg. 2006, 118, 1458–1466.
27. Cervelli, V.; Garcovich, S.; Bielli, A.; Cervelli, G.; Curcio, B.C.; Scioli, M.G.; Orlandi, A.; Gentile, P. The effect of autologous activated platelet rich plasma (AA-PRP) injection on pattern hair loss: Clinical and histomorphometric evaluation. BioMed Res. Int. 2014, 2014, 760709.
28. Gkini, M.A.; Kouskoukis, A.E.; Tripsianis, G.; Rigopoulos, D.; Kouskoukis, K. Study of platelet-rich plasma injections in the treatment of androgenetic alopecia through an one-year period. J. Cutan. Aesthet. Surg. 2014, 7, 213–219.
29. Born, G.V.R. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962, 194, 927–929.
30. Kiso, M.; Hamazaki, T.S.; Itoh, M.; Kikuchi, S.; Nakagawa, H.; Okochi, H. Synergistic effect of PDGF and FGF2 for cell proliferation and hair inductive activity in murine vibrissal dermal papilla in vitro. J. Dermatol. Sci. 2015, 79, 110–118.
31. Hodak, E.; Gottlieb, A.B.; Anzilotti, M.; Krueger, J.G. The insulin-like growth factor 1 receptor is expressed by epithelial cells with proliferative potential in human epidermis and skin appendages: Correlation of increased expression with epidermal hyperplasia. J. Investig. Dermatol. 1996, 106, 564–570.
32. Ristow, H.J.; Messmer, T.O. Basic fibroblast growth-factor and insulin-like growth factor-I are strong mitogens for cultured mouse keratinocytes. J. Cell Physiol. 1988, 137, 277–284.
33. Matsumoto, K.; Hashimoto, K.; Hashiro, M.; Yoshimasa, H.; Yoshikawa, K. Modulation of growth and differentiation in normal human keratinocytes by transforming growth-factor-β. J. Cell Physiol. 1990, 145, 95–101.
34. Shipley, G.D.; Pittelkow, M.R.; Wille, J.J.; Scott, R.E.; Moses, H.L. Reversible inhibition of normal human prokeratinocyte proliferation by type-β transforming growth factor-growth inhibitor in serum-free medium. Cancer Res. 1986, 46, 2068–2071.
35. Pierce, G.F.; Mustoe, T.A.; Lingelbach, J.; Masakowski, V.R.; Griffin, G.L.; Senior, R.M.; Deuel, T.F. Platelet-derived growth-factor and transforming growth factor-β enhance tissue-repair activities by unique mechanisms. J. Cell Biol. 1989, 109, 429–440.
36. Li, Z.J.; Choi, H.I.; Choi, D.K.; Sohn, K.C.; Im, M.; Seo, Y.J.; Lee, Y.H.; Lee, J.H.; Lee, Y. Autologous platelet-rich plasma: A potential therapeutic tool for promoting hair growth. Dermatol. Surg. 2012, 38, 1040–1046.
37. Greco, V.; Chen, T.; Rendl, M.; Schober, M.; Pasolli, H.A.; Stokes, N.; Dela Cruz-Racelis, J.; Fuchs, E. A two-step mechanism for stem cell activation during hair regeneration. Cell Stem Cell 2009, 4, 155–169.
38. Robinson, M.J.; Cobb, M.H. Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol. 1997, 9, 180– 186.
39. Lichtenberger, B.M.; Mastrogiannaki, M.; Watt, F.M. Epidermal β-catenin activation remodels the dermis via paracrine signalling to distinct fibroblast lineages. Nat. Commun. 2016, 7, 1–13.
40. Ahmad, S.; Singh, N.; Glazer, R.I. Role of AKT1 in 17β-estradiol- and insulin-like growth factor 1 (IGF-1)-dependent proliferation and prevention of apoptosis in MCF-7 breast carcinoma cells. Biochem. Pharmacol. 1999, 58, 425–430.
41. Yang, J.; Zhao, S.L.; Yang, X.L.; Zhang, H.; Zheng, P.; Wu, H. Inhibition of B-cell apoptosis is mediated through increased expression of Bcl-2 in patients with rheumatoid arthritis. Int. J. Rheum. Dis. 2016, 19, 134– 140.
42. Gentile, P.; Garcovich, S.; Bielli, A.; Scioli, M.G.; Orlandi, A.; Cervelli, V. The effect of platelet-rich plasma in hair regrowth: A randomized placebo-controlled trial. Stem Cells Transl. Med. 2015, 4, 1317–1323.
43. Hamberg, M.; Svensson, J.; Samuelsson, B. Thromboxanes—New group of biologically-active compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. Sci. USA 1975, 72, 2994–2998.
44. Nedelec, B.; Hou, Q.; Sohbi, I.; Choinière, M.; Beauregard, G.; Dykes, R.W. Sensory perception and neuroanatomical structures in normal and grafted skin of burn survivors. Burns 2005, 31, 817–830.
45. Campagnolo, L.; Costanza, G.; Francesconi, A.; Arcuri, G.; Moscatelli, I.; Orlandi, A. Sortilin expression is essential for pro-nerve growth factorinduced apoptosis of rat vascular smooth muscle cells. PLoS ONE 2014, 9, e84969.
46. Ferlosio, A.; Arcuri, G.; Doldo, E.; Scioli, M.G.; de Falco, S.; Spagnoli, L.G.; Orlandi, A. Age related increase of stem marker expression influences vascular smooth muscle cell properties. Atherosclerosis 2012, 224, 51– 57.
47. L-carnitine improves postischemic blood flow recovery and arteriogenetic revascularization and reduces endothelial NADPH-oxidase 4-mediated superoxide production. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 426–435.
48. L-carnitine enhances wound healing and counteracts microvascular endothelial cell dysfunction. PLoS ONE 2015, 10, e0140697.